GlassScriptPhysician profile
Parissa I Vassef
NPI 1356630370
$27,207.21
in general payments reported to CMS, 2019-2025
69 companies · $5,293 in 2025
The $5,293 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,623 · 2020: $2,232 · 2021: $2,609 · 2022: $4,042 · 2023: $5,266 · 2024: $5,142 · 2025: $5,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,327.53 |
| Education | $374.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,370.76 | 2019-2025 | |
| Abbvie INC. | $2,026.47 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Neurocrine Biosciences, INC. | $1,950.06 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,810.48 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,691.08 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $1,462.05 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Mdd US Operations, LLC | $1,298.92 | 2019-2025 | Gocovri, Gocovri |
| Emd Serono, INC. | $1,023.99 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $842.10 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $839.23 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $810.97 | 2021-2025 | Xcopri |
| Lilly USA, LLC | $779.89 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Lundbeck LLC | $767.56 | 2020-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $766.06 | 2019-2025 | Nuplazid |
| Csl Behring | $666.00 | 2019-2025 | Hizentra |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $575.39 | 2022-2025 | |
| Celgene Corporation | $548.30 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $512.83 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $443.97 | 2019-2025 | |
| Argenx US, INC. | $360.13 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $326.95 | 2021-2025 | Ponvory, Hetlioz |
| Sunovion Pharmaceuticals INC. | $325.48 | 2019-2022 | |
| Allergan, INC. | $317.74 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $312.57 | 2019-2022 | |
| Horizon Therapeutics Plc | $286.62 | 2022-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $277.09 | 2022-2024 | Amvuttra |
| Takeda Pharmaceuticals U.S.A., INC. | $271.84 | 2020-2024 | Gammagard, Hyqvia |
| Eisai INC. | $258.52 | 2019-2024 | |
| Kyowa Kirin, INC. | $258.10 | 2019-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $185.74 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $174.39 | 2022 | |
| Upsher-Smith Laboratories LLC | $172.25 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $171.33 | 2023 | Aptiom |
| Grifols USA, LLC | $156.90 | 2019-2023 | Gamunex-C |
| Amylyx Pharmaceuticals, INC. | $143.91 | 2023-2024 | Relyvrio |
| Tanabe Pharma America, INC. | $135.57 | 2021-2025 | Radicava |
| Biohaven Pharmaceuticals, INC. | $132.68 | 2021 | |
| Scilex Pharmaceuticals INC. | $126.23 | 2019-2024 | Ztlido |
| Acorda Therapeutics, INC | $125.54 | 2019-2023 | Inbrija |
| Merz Pharmaceuticals, LLC | $123.39 | 2024-2025 | Xeomin, Inbrija |
| Aucta Pharmaceuticals, INC. | $113.78 | 2025 | Motpoly Xr |
| Astrazeneca Pharmaceuticals LP | $109.13 | 2021-2025 | Wainua |
| Abbott Laboratories | $100.79 | 2020-2024 | Infinity |
| Janssen Pharmaceuticals, INC | $98.75 | 2022-2023 | Ponvory |
| Mallinckrodt Enterprises LLC | $93.48 | 2019 | |
| Livanova USA, INC. | $89.70 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $80.91 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $72.40 | 2023 | Dysport |
| Mallinckrodt Hospital Products INC. | $65.14 | 2020 | |
| Neurelis, INC. | $64.26 | 2021-2023 | Valtoco |
| Averitas Pharma INC. | $55.74 | 2024 | Qutenza |
| Adamas Pharmaceuticals, INC. | $36.14 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $35.81 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $33.98 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $33.84 | 2025 | Purified Cortrophin Gel |
| Corium, LLC | $29.19 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $28.80 | 2025 | Crexont |
| Catalyst Pharmaceuticals, INC. | $27.27 | 2023 | Firdapse |
| Vertical Pharmaceuticals, LLC | $23.23 | 2019 | |
| Neuropace, INC. | $22.73 | 2023 | |
| Octapharma USA, INC. | $22.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.83 | 2020 | |
| Aquestive Therapeutics, INC. | $20.62 | 2021 | |
| Nevro Corp. | $18.98 | 2023 | Senza |
| Forte Bio-Pharma LLC | $18.78 | 2025 | Tanlor |
| Medtronic USA, INC. | $17.03 | 2019 | |
| Boston Scientific Corporation | $16.74 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.59 | 2019 | |
| Assertio Therapeutics, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parissa Vassef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.